Avenue Therapeutics, Inc.(ATXI)Earnings, Financials & Key Ratios
ATXI•NASDAQ
$0.55
$2M mkt cap·Price updated May 6, 2026
AboutAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.Show more
- Revenue$0
- EBITDA-$12M
- Net Income-$12M-12.3%
- EPS (Diluted)-0.90+98.8%
- ROE-928.45%-75.4%
ATXI Key Insights
Avenue Therapeutics, Inc. (ATXI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ATXI Price & Volume
Avenue Therapeutics, Inc. (ATXI) stock price & volume — 10-year historical chart
Loading chart...
ATXI Growth Metrics
Avenue Therapeutics, Inc. (ATXI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM73.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM123.81%
Return on Capital
10 Years-422.59%
5 Years-424.57%
3 Years-626.79%
Last Year-899.04%
ATXI Peer Comparison
Avenue Therapeutics, Inc. (ATXI) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 COLL | 1.18B | 36.51 | 21.10 | 23.62% | 8.05% | 24.11% | 3.12 | |
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% | |||
 XTLB | 357.58K | 3.25 | -0.34 | -227.72% | -25.53% | 0.03 | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 MCK | 91.09B | 743.67 | 28.91 | 16.22% | 1.09% |
Compare ATXI vs Peers
Avenue Therapeutics, Inc. (ATXI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATXI Income Statement
Avenue Therapeutics, Inc. (ATXI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4M |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 1.4M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | 100% |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 2.38M | 6.7M | 21.82M | 26.27M | 5.21M | 3.74M | 8.04M | 14.54M | 11.28M | 5.33M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 997K | 3.62M | 4.12M | 3.07M | 2.35M | 2.48M | 5.34M | 4.18M | 4.64M | 3.99M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.38M | 7.8M | 17.7M | 23.19M | 2.87M | 1.25M | 2.7M | 10.36M | 6.64M | 1.34M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -99K | 175K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.38M▲ 0% | -11.42M▼ 380.5% | -21.82M▼ 91.0% | -26.27M▼ 20.4% | -5.21M▲ 80.2% | -3.74M▲ 28.3% | -8.04M▼ 115.2% | -14.54M▼ 80.8% | -11.28M▲ 22.4% | -3.93M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | -279.77% |
| Operating Income Growth % | 50.92% | -380.48% | -91.02% | -20.39% | 80.15% | 28.29% | -115.17% | -80.78% | 22.4% | - |
| EBITDA | 0 | 0 | 0 | -25.91M | -5.15M | 0 | -2.44M | 0 | -11.7M | -3.85M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | -274.22% |
| EBITDA Growth % | -100% | - | - | - | 80.12% | 100% | - | 100% | - | 33.48% |
| D&A (Non-Cash Add-back) | 2.38M | 11.42M | 21.82M | 0 | 0 | 3.74M | 0 | 14.54M | 0 | 0 |
| EBIT | -2.56M | -11.88M | -21.55M | -25.91M | -5.15M | -3.73M | -2.44M | -10.49M | -11.7M | -3.85M |
| Net Interest Income | 0 | -287K | 0 | 357K | 62K | 7K | -1.14M | 126K | 176K | 121K |
| Interest Income | 0 | 88K | 93K | 357K | 62K | 7K | 20K | 126K | 176K | 121K |
| Interest Expense | 612K | 375K | 0 | 0 | 0 | 0 | 1.16M | 0 | 0 | 0 |
| Other Income/Expense | -800K | -837K | 268K | 357K | 62K | 7K | 4.44M | 4.05M | -413K | 157K |
| Pretax Income | -3.18M▲ 0% | -12.26M▼ 285.8% | -21.55M▼ 75.8% | -25.91M▼ 20.2% | -5.15M▲ 80.1% | -3.73M▲ 27.6% | -3.6M▲ 3.4% | -10.49M▼ 191.1% | -11.7M▼ 11.5% | -3.77M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | -268.59% |
| Income Tax | 0 | 0 | -268K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 1.24% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.18M▲ 0% | -12.26M▼ 285.8% | -21.55M▼ 75.8% | -25.91M▼ 20.2% | -5.15M▲ 80.1% | -3.73M▲ 27.6% | -3.55M▲ 4.8% | -10.38M▼ 192.1% | -11.65M▼ 12.3% | -3.74M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | -266.67% |
| Net Income Growth % | 39.21% | -285.84% | -75.79% | -20.23% | 80.12% | 27.57% | 4.8% | -192.15% | -12.29% | 73.18% |
| Net Income (Continuing) | -3.18M | -12.26M | -21.55M | -25.91M | -5.15M | -3.73M | -3.6M | -10.49M | -11.7M | -3.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -639K | -928K | -941K | -1.25M |
| EPS (Diluted) | -5.39▲ 0% | -27.71▼ 414.1% | -31.17▼ 12.5% | -24.38▲ 21.8% | -4.65▲ 80.9% | -3.29▲ 29.2% | -121.91▼ 3605.5% | -73.48▲ 39.7% | -0.90▲ 98.8% | -1.18▲ 0% |
| EPS Growth % | 42.66% | -414.1% | -12.49% | 21.78% | 80.93% | 29.25% | -3605.47% | 39.73% | 98.78% | 123.81% |
| EPS (Basic) | -5.39 | -27.71 | -31.17 | -24.38 | -4.65 | -3.29 | -121.91 | -73.60 | -0.90 | - |
| Diluted Shares Outstanding | 589.43K | 442.33K | 682.61K | 1.05M | 1.1M | 1.13M | 29.14K | 141.22K | 12.95M | 3.18M |
| Basic Shares Outstanding | 589.43K | 442.33K | 682.61K | 1.05M | 1.1M | 1.13M | 29.14K | 141K | 12.95M | 3.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ATXI Balance Sheet
Avenue Therapeutics, Inc. (ATXI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 197K | 22.17M | 4.53M | 8.91M | 3.25M | 3.96M | 6.84M | 1.85M | 2.67M | 3.71M |
| Cash & Short-Term Investments | 197K | 21.78M | 2.67M | 8.74M | 3.13M | 3.76M | 6.71M | 1.78M | 2.59M | 3.71M |
| Cash Only | 197K | 11.78M | 2.67M | 8.74M | 3.13M | 3.76M | 6.71M | 1.78M | 2.59M | 3.71M |
| Short-Term Investments | 0 | 10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 90K | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 51.99 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 1.7M | 0 | 0 | 0 | 0 | 0 | 78K | 0 |
| Total Non-Current Assets | 0 | 0 | 1.85M | 170K | 113K | 0 | 0 | 67K | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 1.85M | 170K | 113K | 0 | 0 | 67K | 0 | 0 |
| Total Assets | 197K▲ 0% | 22.17M▲ 11153.8% | 4.53M▼ 79.6% | 8.91M▲ 97.0% | 3.25M▼ 63.6% | 3.96M▲ 22.0% | 6.84M▲ 72.9% | 1.85M▼ 73.0% | 2.67M▲ 44.4% | 3.73M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.40x |
| Asset Growth % | 1307.14% | 11153.81% | -79.59% | 97.02% | -63.6% | 22.03% | 72.85% | -72.97% | 44.43% | 78.34% |
| Total Current Liabilities | 6.42M | 2.79M | 5.16M | 2.12M | 886K | 509K | 3.58M | 1.2M | 816K | 1.42M |
| Accounts Payable | 334K | 1.54M | 3.09M | 354K | 172K | 304K | 150K | 401K | 155K | 490K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 3.85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.66M | 0 | 0 | 1M | 0 | 24K | 2.61M | 784K | 34K | 391K |
| Current Ratio | 0.03x | 7.95x | 0.88x | 4.22x | 3.66x | 7.78x | 1.91x | 1.55x | 3.27x | 3.27x |
| Quick Ratio | 0.03x | 7.95x | 0.88x | 4.22x | 3.66x | 7.78x | 1.91x | 1.55x | 3.27x | 3.27x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 51.99 |
| Total Non-Current Liabilities | 2.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 2.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 8.45M | 2.79M | 5.16M | 2.12M | 886K | 509K | 3.58M | 1.2M | 816K | 1.42M |
| Total Debt | 5.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 5.68M | -11.78M | -2.67M | -8.74M | -3.13M | -3.76M | -6.71M | -1.78M | -2.59M | -3.71M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.96x |
| Interest Coverage | -3.88x | -30.46x | - | - | - | - | -6.93x | - | - | - |
| Total Equity | -8.25M▲ 0% | 19.38M▲ 335.0% | -631K▼ 103.3% | 6.8M▲ 1177.7% | 2.36M▼ 65.3% | 3.45M▲ 46.3% | 3.27M▼ 5.4% | 654K▼ 80.0% | 1.86M▲ 183.8% | 2.3M▲ 0% |
| Equity Growth % | -60.62% | 334.97% | -103.26% | 1177.65% | -65.31% | 46.29% | -5.36% | -79.98% | 183.79% | 220.07% |
| Book Value per Share | -13.99 | 43.81 | -0.92 | 6.49 | 2.14 | 3.05 | 112.10 | 4.63 | 0.14 | 0.72 |
| Total Shareholders' Equity | -8.25M | 19.38M | -631K | 6.8M | 2.36M | 3.45M | 3.9M | 1.58M | 2.8M | 3.56M |
| Common Stock | 1K | 1K | 1K | 2K | 2K | 0 | 0 | 3K | 0 | 0 |
| Retained Earnings | -8.4M | -20.66M | -42.21M | -68.12M | -73.27M | -77M | -80.55M | -90.93M | -102.58M | -104.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 49K | 1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -639K | -928K | -941K | -1.25M |
ATXI Cash Flow Statement
Avenue Therapeutics, Inc. (ATXI) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.63M | -6.8M | -18.22M | -26.26M | -4.61M | -3.75M | -7.6M | -9.45M | -9.03M | -9.03M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -82.35% | -316.79% | -167.8% | -44.15% | 82.43% | 18.71% | -102.56% | -24.42% | 4.5% | 334.56% |
| Net Income | -3.18M | -12.26M | -21.55M | -25.91M | -5.15M | -3.73M | -3.6M | -10.38M | -11.7M | -3.74M |
| Depreciation & Amortization | 0 | 174K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 28K | 604K | 1.54M | 1.84M | 710K | 442K | 649K | 906K | 1.24M | 1.04M |
| Deferred Taxes | 0 | 277K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 435K | 2.32M | 412K | 61K | 0 | 0 | -5.05M | 310K | 1.25M | 1.42M |
| Working Capital Changes | 1.08M | 2.08M | 1.79M | -2.25M | -172K | -461K | 408K | -290K | 179K | -422K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -90K | 90K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 15K | 2.23M | 1.13M | -3.23M | -229K | 0 | 0 | -360K | 0 | -73K |
| Cash from Investing | 0 | -10M | 10M | 0 | -1M | 0 | 0 | -3M | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | -1M | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -10K | -10M | 0 | 0 | 0 | 0 | -3M | 0 | 0 |
| Cash from Financing | 1.81M | 28.39M | -895K | 32.33M | 0 | 4.38M | 10.54M | 7.53M | 9.84M | 2.85M |
| Debt Issued (Net) | 1.87M | -3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1.76M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -1.1M | 0 | 0 | 0 |
| Other Financing | -58K | -6.56M | -895K | -2.67M | 0 | -663K | 148K | 1K | 8.21M | 0 |
| Net Change in Cash | 183K▲ 0% | 11.59M▲ 6230.6% | -9.11M▼ 178.6% | 6.07M▲ 166.7% | -5.61M▼ 192.4% | 631K▲ 111.2% | 2.94M▲ 366.7% | -4.92M▼ 267.2% | 811K▲ 116.5% | 1.11M▲ 0% |
| Free Cash Flow | -1.63M▲ 0% | -6.8M▼ 316.8% | -18.22M▼ 167.8% | -26.26M▼ 44.2% | -5.61M▲ 78.6% | -3.75M▲ 33.2% | -7.6M▼ 102.6% | -12.45M▼ 63.9% | -9.03M▲ 27.5% | -1.74M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | -124.15% |
| FCF Growth % | 58.1% | -316.79% | -167.8% | -44.15% | 78.62% | 33.19% | -102.56% | -63.92% | 27.51% | 83.53% |
| FCF per Share | -2.77 | -15.38 | -26.69 | -25.06 | -5.10 | -3.31 | -260.72 | -88.17 | -0.70 | -0.70 |
| FCF Conversion (FCF/Net Income) | 0.51x | 0.55x | 0.85x | 1.01x | 0.90x | 1.01x | 2.14x | 0.91x | 0.77x | 0.47x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATXI Key Ratios
Avenue Therapeutics, Inc. (ATXI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -220.23% | -229.86% | -839.94% | -112.48% | -128.43% | -105.76% | -529.44% | -928.45% | -160.63% |
| Return on Invested Capital (ROIC) | - | -340.79% | -761.73% | - | - | - | - | - | - | 309.45% |
| Gross Margin | - | - | - | - | - | - | - | - | - | 100% |
| Net Margin | - | - | - | - | - | - | - | - | - | -266.67% |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Interest Coverage | -3.88x | -30.46x | - | - | - | - | -6.93x | - | - | - |
| FCF Conversion | 0.51x | 0.55x | 0.85x | 1.01x | 0.90x | 1.01x | 2.14x | 0.91x | 0.77x | 0.47x |
ATXI Frequently Asked Questions
Avenue Therapeutics, Inc. (ATXI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Avenue Therapeutics, Inc. (ATXI) reported $1.4M in revenue for fiscal year 2024.
Avenue Therapeutics, Inc. (ATXI) grew revenue by 0.0% over the past year. Growth has been modest.
Avenue Therapeutics, Inc. (ATXI) reported a net loss of $3.7M for fiscal year 2024.
Dividend & Returns
Avenue Therapeutics, Inc. (ATXI) has a return on equity (ROE) of -928.4%. Negative ROE indicates the company is unprofitable.
Avenue Therapeutics, Inc. (ATXI) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More ATXI
Avenue Therapeutics, Inc. (ATXI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates